The cardiometabolic disease market was valued at USD 34.10 Billion in 2024 driven by the rising prevalence of conditions like obesity, diabetes, and cardiovascular diseases as well as risk factors such as sedentary lifestyle and aging population across the 8 major markets. It is expected to grow at a CAGR of 5.40% during the forecast period 2025-2034 and attain a market value of USD 57.70 Billion by 2034.
Treatment includes making lifestyle modifications, taking medications such as antihypertensives and metformin, and potentially undergoing surgical procedures including bariatric surgery. Ongoing surveillance and individualized approaches are essential for controlling risk factors and enhancing clinical outcomes. Medications can be given orally for high blood pressure and type 2 diabetes, or by injections for precise management of diabetes. In cases of emergencies such as heart failure, intravenous treatments may be administered. Modern technologies such as continuous glucose monitoring systems provide immediate management choices. The selection of how to administer medication relies on the patient's condition, adherence, and the treatment's efficacy.
The United States is expected to dominate the market share. Cardiometabolic diseases such as obesity, diabetes, and cardiovascular diseases are common in this region due to lifestyle behaviors but are aided by a well-developed healthcare system and research endeavors. Increased public health efforts and new treatment approaches are set to fuel the market growth in the region in the coming years.
The market in the Japan and India region is rapidly expanding because both the nations are concentrating on public health programs and advancements in treatment options to tackle these issues. In Japan, as the population ages, there is an increase in age-related cardiometabolic conditions, while in India, the growth of urban areas is causing a rise in obesity.
Other players in the market are Biocrates Life Sciences AG, Alnylam Pharmaceuticals, Inc, Arrowhead Pharmaceuticals, Inc, Dicerna Pharmaceuticals, Inc, Cardax, Inc, Boehringer Ingelheim International GmbH, Kowa Company, Ltd, Allergan Inc, AstraZeneca Plc, Pfizer Inc, and Sanofi SA.
This product will be delivered within 3-5 business days.
Cardiometabolic Disease Market Overview
Cardiometabolic disease includes obesity, diabetes, high blood pressure, and heart diseases, with shared risk factors such as unhealthy diet and genetics. Common types of cardiometabolic diseases include chronic heart failure, high blood pressure, type 2 diabetes, and obesity. Chronic heart failure occurs when the heart is unable to pump efficiently, whereas hypertension increases the likelihood of heart attacks. Comprehending and tackling these linked factors are crucial for successful prevention and control of cardiometabolic illnesses.Treatment includes making lifestyle modifications, taking medications such as antihypertensives and metformin, and potentially undergoing surgical procedures including bariatric surgery. Ongoing surveillance and individualized approaches are essential for controlling risk factors and enhancing clinical outcomes. Medications can be given orally for high blood pressure and type 2 diabetes, or by injections for precise management of diabetes. In cases of emergencies such as heart failure, intravenous treatments may be administered. Modern technologies such as continuous glucose monitoring systems provide immediate management choices. The selection of how to administer medication relies on the patient's condition, adherence, and the treatment's efficacy.
Cardiometabolic Disease Market Growth Drivers
Rising Prevalence of Cardiometabolic Disorders Drives Market Growth
The rising occurrence of cardiometabolic conditions is fueling expansion in the market for related diseases. The Centers for Disease Control and Prevention states that cardiometabolic diseases impact a significant number of adults in the United States, with about 11% diagnosed with diabetes and 10% diagnosed with cardiovascular disease (such as coronary heart disease, heart failure, or stroke). The increase in the prevalence of obesity, type 2 diabetes, and cardiovascular diseases is a result of lifestyle shifts towards poor diets and lack of physical activity. Further, older populations are more susceptible to these conditions, placing additional strain on healthcare systems. This has led to increased spending on healthcare and a need for efficient therapies, thereby stimulating innovation in the market.Advancements in Treatment Options to Augment Cardiometabolic Disease Market Demand
Progress in treatment, such as the development of new medications for diabetes and heart health, is enhancing patient outcomes. In March 2024, the FDA approved Wegovy (semaglutide) injection for reducing the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and obesity/overweight. A calorie-restricted diet and increased physical activity should be followed while taking the medication for maximum effectiveness. Additionally, the rising preference for customized combination treatments and advancements in disease management through digital health solutions and telemedicine services are anticipated to propel the market growth in the forecast period. Changing clinical recommendations are guaranteeing that patients are getting the best possible treatment, showing a move towards individualized and comprehensive healthcare for improved handling of cardiometabolic conditions.Cardiometabolic Disease Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:Integration of Artificial Intelligence (AI) to Impact the Market Landscape Significantly
The inclusion of AI is transforming the market for cardiometabolic disease, enhancing accuracy in diagnosis, customization of treatment, and patient support. In March 2024, UMass Memorial Health announced a partnership with Google Cloud to utilize AI, ML, and data analytics for personalized care in cardiometabolic health. By leveraging data and predictive analytics, UMass Memorial Health seeks to revolutionize healthcare delivery and improve outcomes for cardiometabolic patients. AI algorithms examine extensive healthcare data to recognize patterns and potential risks, allowing for earlier detection and personalized treatment strategies.Expansion of Combination Therapies Likely to Elevate the Cardiometabolic Disease Market Value
The market is expanding in combination therapies to address various pathways in diseases such as hypertension, diabetes, and obesity, leading to better treatment effectiveness and patient compliance. This comprehensive method acknowledges the intricacy of cardiometabolic conditions, highlighting the incorporation of treatment plans for improved results.Rising Collaboration and Partnerships to Support Market Growth
Pharmaceutical companies, technology firms, and healthcare providers are collaborating to create holistic solutions. In September 2023, The Broad Institute of MIT and Harvard partnered with Novo Nordisk to research diabetes and cardiometabolic diseases. The alliance will work on programs over three years: identifying drug targets for type 2 diabetes subtypes and genetic causes of cardiac fibrosis. These conditions affect millions in the US and can lead to heart dysfunction. These partnerships allow for sharing knowledge, combining resources, and developing innovative therapies and diagnostic tools. Public-private partnerships are also beginning to develop to assist research and community health programs.Growing Importance of Dietary Interventions Projected to Boost Cardiometabolic Disease Market Size
The importance of dietary interventions in managing cardiometabolic diseases is increasing, emphasizing the importance of balanced diets that are nutrient rich. Certain eating habits such as the Mediterranean and DASH diets have shown to be successful in enhancing metabolic well-being. Education and counseling on nutrition are essential elements of treatment plans. The emergence of functional foods and supplements catering to metabolic health is generating fresh market prospects.Cardiometabolic Disease Market Segmentation
“Cardiometabolic Disease Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:Market Breakup by Disease Type
- Chronic/Congestive Heart Failure
- Hypertension
- Type 2 Diabetes
- Obesity
- Others
Market Breakup by Treatment Type
- ACE Inhibitors
- Diuretics
- Glucophage
- Others
Market Breakup by Route of Administration
- Oral
- Intravenous
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Japan
- India
Cardiometabolic Disease Market Share
Market Segmentation Based on the Disease Type to Witness Growth
The cardiometabolic disease market can be divided based on disease type, such as chronic/congestive heart failure, hypertension, type 2 diabetes, obesity, and other conditions. Type 2 diabetes is widespread worldwide because of inactive lifestyles and unhealthy eating habits, resulting in growing emphasis on treatment and research for the disease. Pharmaceutical companies are increasingly focusing on creating new treatments for diabetes and related problems such as heart and kidney issues.Distribution Channel Segment Represents Substantial Market Share
Based on the distribution chancel, the market is divided into hospital pharmacy, retail pharmacy, online pharmacy, and others. Retail pharmacies hold a significant market share as they are frequently utilized for prescription renewals and advice, whereas online pharmacies are becoming more popular for delivering medications to the patient’s home. Hospital pharmacies play a vital role in providing specialized medications and acute care services for a wide range of patients with cardiometabolic diseases.Cardiometabolic Disease Market Analysis by Region
Based on region, the market report covers United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India.The United States is expected to dominate the market share. Cardiometabolic diseases such as obesity, diabetes, and cardiovascular diseases are common in this region due to lifestyle behaviors but are aided by a well-developed healthcare system and research endeavors. Increased public health efforts and new treatment approaches are set to fuel the market growth in the region in the coming years.
The market in the Japan and India region is rapidly expanding because both the nations are concentrating on public health programs and advancements in treatment options to tackle these issues. In Japan, as the population ages, there is an increase in age-related cardiometabolic conditions, while in India, the growth of urban areas is causing a rise in obesity.
Leading Players in the Cardiometabolic Disease Market
The key features of the market report include patent analysis, grant analysis, funding, and investment analysis, clinical trials analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:Eli Lilly and Company
Eli Lilly and Company, based in Indianapolis, is a pharmaceutical company that develops and sells healthcare products for various conditions. In July 2023, they announced an agreement to acquire Versanis Bio, a biopharmaceutical company focusing on cardiometabolic diseases.Novartis AG
Novartis AG is a Swiss multinational pharmaceutical company in Basel. The company got FDA approval in July 2023 to expand the use of its drug Leqvio® (inclisiran). The injectable medicine is now indicated for adults with high LDL-C at risk of heart disease, as an addition to diet and statins for hyperlipidemia treatment.Novo Nordisk A/S
Novo Nordisk A/S, a Danish pharmaceutical company, focuses on discovering and developing biological medicines for diabetes, haemophilia, growth hormone disorders, rare blood and endocrine diseases, and obesity. In September 2023, Novo Nordisk partnered with The Broad Institute to research diabetes and cardiometabolic diseases in the United States. The alliance aims to identify drug targets for type 2 diabetes subtypes and genetic causes of cardiac fibrosis.Merck & Co., Inc
Merck & Co., Inc. is an American pharmaceutical company based in Rahway, New Jersey. Merck focuses on developing and marketing prescription medicines, biologic therapies, vaccines, and animal health products. Their products target various health conditions such as cardiovascular issues, cancer, immune disorders, infectious diseases, and diabetes. In June 2024, Merck announced that they are prioritizing opportunities in the cardiometabolic drugs market, including weight-loss treatments.Other players in the market are Biocrates Life Sciences AG, Alnylam Pharmaceuticals, Inc, Arrowhead Pharmaceuticals, Inc, Dicerna Pharmaceuticals, Inc, Cardax, Inc, Boehringer Ingelheim International GmbH, Kowa Company, Ltd, Allergan Inc, AstraZeneca Plc, Pfizer Inc, and Sanofi SA.
Key Questions Answered in the Cardiometabolic Disease Market Report
- What was the cardiometabolic disease market value in 2023?
- What is the cardiometabolic disease market forecast outlook for 2025-2034?
- What are the regional markets covered in the report?
- What is the market segmentation based on disease type?
- What is the market segmentation based on distribution channels?
- What is the market breakup based on treatment type?
- What is the market breakup based on route of administration?
- What are the major factors aiding the cardiometabolic disease market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the major drivers, opportunities, and restraints in the market?
- What are the major trends influencing the market?
- Which regional market is expected to dominate the market share in the forecast period?
- Which country is likely to experience elevated growth during the forecast period?
- Who are the key players involved in the cardiometabolic disease market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
More Insights On
Dry Eye Disease Market
Von Hippel-Lindau Disease Market
Parkinson’s Disease Market
Wilson’s Disease Market
Sandhoff Disease Market
Tay-Sachs Disease Market
Peripheral Artery Disease Market
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Cardiometabolic Disease Market Overview: 8 Major Market
4 Vendor Positioning Analysis
5 Cardiometabolic Disease: Disease Overview
6 Patient Profile
7 Cardiometabolic Disease Market Epidemiology Scenario and Forecast - 8 Major Markets
8 Cardiometabolic Disease Market Landscape: 8 Major Market*
9 Cardiometabolic Disease Market Challenges and Unmet Needs
11 Cardiometabolic Disease: Market Dynamics
12 Cardiometabolic Disease Market Segmentation: 8 Major Markets
13 United States Cardiometabolic Disease Market (218-2034)
14 EU-4 and United Kingdom Cardiometabolic Disease Market (218-2034)
15 Japan Cardiometabolic Disease Market
16 India Cardiometabolic Disease Market
17 Regulatory Framework
18 Patent Analysis
19 Clinical Trial Analysis
20 Grant Analysis
21 Funding and Investment Analysis
22 Strategic Initiatives
23 Supplier Landscape
24 Cardiometabolic Disease Market - Distribution Model (Additional Insight)
26 Payment Methods (Additional Insight)
Companies Mentioned
- Eli Lilly and Company
- Novartis AG
- Novo Nordisk A/S
- Merck & Co., Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 400 |
| Published | June 2025 |
| Forecast Period | 2025 - 2034 |
| Estimated Market Value ( USD | $ 34.1 Billion |
| Forecasted Market Value ( USD | $ 57.7 Billion |
| Compound Annual Growth Rate | 5.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 4 |
